Entering 2023, the private venture-backed life sciences and healthcare landscape undoubtedly looks and feels different than it did during the fast-paced, valuation-rich days of 2021. Silicon Valley Bank’s most recent Healthcare Investment and Exits report revealed that 2022 was still the second-largest year on record for venture capital investment into healthcare companies in the US, UK and EU. However, investment dollars dropped 34% from 2021’s peak, and public markets were eerily quiet, with only 31 private venture-backed healthcare IPOs versus 174. READ MORE